Regulation of sensitivity or resistance for apoptosis by death receptor ligand systems is a key control mechanism in the hematopoietic system. Dysfunctional or deregulated apoptosis can potentially contribute to the development of immune deficiencies, autoimmune diseases, and leukemia. Control of homeostasis starts at the level of hematopoietic stem cells (HSC). To this end, we found that CD34 þ hematopoietic progenitor cells are constitutively resistant to CD95-mediated apoptosis and cannot be sensitized during short-term culture to death receptor-mediated apoptosis by cytokines. Detailed analysis of the death machinery revealed that CD34 þ cells do not express caspase-8a/b, a crucial constituent of the death-inducing signaling complex (DISC) of death receptors. Instead, we found a smaller splice variant termed caspase-8L to be present in HSC. Forced expression of caspase-8L using a recombinant lentiviral vector was able to protect hematopoietic cells from death receptor-induced apoptosis even in the presence of caspase-8a/b. Furthermore, we found that caspase-8L is recruited to the DISC after CD95 triggering, thereby preventing CD95 from connecting to the caspase cascade. These results demonstrate an antiapoptotic function of caspase-8L and suggest a critical role as apoptosis regulator in HSC. Similar to CD34 þ HSC, stem cell-derived leukemic blasts from AML(M0) patients only expressed caspase-8L. Additionally we found, caspase-8L expression in several AML and ALL samples. Thus, caspase-8L expression might explain constitutive resistance to CD95-mediated apoptosis in CD34 þ progenitor cells and might participate in the development of stem cell-derived and other leukemias by providing protection from regulatory apoptosis.
Introduction
The CD95/CD95L system is considered to be a key regulator of the immune response by controlling the number of activated T-and B cells (Owen and Jenkinson, 1992; Debatin et al., 1994; Krammer et al., 1994; Dhein et al., 1995; Krammer, 2000) . Binding of CD95L to CD95 on the surface of mature T-and B cells induces an apoptotic program eliminating excess immune cells from the periphery. Furthermore, mature granulocytes have been shown to be CD95 sensitive, indicating a role of this death system also in the regulation of myelopoiesis (Liles et al., 1996) . While the role of CD95 during late stages of hematopoiesis is relatively well characterized, only little is known about the physiological role of CD95 signaling in early hematopoiesis. Consequently, the issue of sensitivity of CD34 þ cells to CD95-mediated apoptosis is still controversial (Sato et al., 1997; Barcena et al., 1999; Josefsen et al., 1999; Kim et al., 2002; Dybedal et al., 2003) . While CD34 þ progenitor cells were found to express CD95 on the surface and CD95-triggering mediated inhibition of colony formation (Maciejewski et al., 1995b) , resistance to CD95-induced cell death has also been described (Kim et al., 2002) . It has even been suggested that CD95L may act as a survival factor on very early progenitor cells (Josefsen et al., 1999) .
As a potential novel mechanism for CD95 resistance, an antiapoptotic splice variant of caspase-8, caspase-8L (Himeji et al., 2002) , was recently detected in human peripheral blood lymphocytes (PBL) by reverse transcriptase (RT)-PCR (Horiuchi et al., 2000) . Caspase-8L mRNA carries a 136 bp insertion between exon 8 and exon 9 of full-length caspase-8 mRNA generated by aberrant splicing of intron 8. The transcript carries a stop codon just after the two N-terminal death effector domains (DEDs), lacking the C-terminal proteolytic domain (Horiuchi et al., 2000) . Functional studies demonstrated that caspase-8L when overexpressed in breast cancer cells can act as an inhibitor of the caspase cascade and apoptosis by interfering with the binding of the proteolytically active caspase-8 to Fas-associated death domain (DD)-containing protein (FADD) (Himeji et al., 2002) . It is important to note that this caspase-8L is distinct from the procaspase-8 isoform, also called procaspase-8L, recruited to the BAP31 complex at the endoplasmic reticulum as described by Breckenridge et al. (2002) .
The consequences of dysregulated apoptosis in hematopoiesis can be severe. Excessive apoptosis in hematopoietic populations was found to play a major role in the pathogenesis of acquired immunodeficiency syndrome (AIDS) (Ameisen and Capron, 1991) and of severe aplastic anemia (SAA) (Maciejewski et al., 1995b; Vibhuti et al., 2002) , whereas ineffective apoptosis has been associated with the development of hematological malignancies (Falk et al., 1992; Wickremasinghe and Hoffbrand, 1999; Straus et al., 2001; Lotem and Sachs, 2002; Debatin et al., 2003) , inflammation, and autoimmunity (Cohen and Eisenberg, 1992; Fisher et al., 1995; Thompson, 1995; Martin et al., 1999; Straus et al., 1999; Vaishnaw et al., 1999) . However, little is known about the regulation of apoptosis at distinct stages of early hematopoiesis. Therefore, we investigated the physiological role of the CD95 pathway in early hematopoiesis. We determined whether isolated, unmanipulated human CD34 þ cells are susceptible to CD95-mediated apoptosis and found that CD34 þ cells, in line with data from Josefsen et al. (1999) , are resistant to CD95-mediated apoptosis and that cytokines such as interferon-g (IFN-g), known to agonize the CD95 pathway, do not lead to CD95 sensitivity of CD34 þ cells in short-term culture. The protection against CD95-mediated apoptosis might be of physiological importance ensuring the maintenance of hematopoietic progenitors. Analysis of the death receptor machinery revealed that hematopoietic progenitors exclusively express caspase-8L, but not casapse-8a/b. Interestingly, we also detected caspase-8L expression in stem cellderived leukemic cells as well as in AML and ALL blasts. Hence, aberrations in the relative levels of different caspase-8 isoforms with distinct pro-and antiapoptotic functions might explain the resistance to receptor-mediated apoptosis in hematopoietic stem cells and leukemias directly derived from this pool, providing a potential detrimental survival benefit for the latter cells.
Results
Constitutive resistance of human CD34 þ hematopoietic stem cells (HSC) to CD95-mediated apoptosis Previously, the CD95 receptor/ligand system has been implicated in the pathogenesis of hematopoietic failure (Maciejewski et al., 1995b; Bouscary et al., 1997; Dror and Freedman, 2001) , although no direct CD95 (apoptosis-) sensitivity of CD34 þ cells has been described so far. We therefore determined CD95 expression and susceptibility to CD95-mediated apoptosis in CD34 þ cells isolated from peripheral blood after G-CSF mobilization. Following isolation, these cells were cryopreserved and stored in liquid nitrogen. After thawing, hematopoietic progenitors were found to express low, but significant, levels of CD95 (Figure 1a ), which increased after treatment with IFN-g (1000 U) for 24 h in vitro (Figure 1b) . Figure 1c shows that CD95 upregulation (5-6-fold) was dose independent at IFN-g concentrations of 200-5000 U. Extending the stimulation time also did not further increase CD95 expression levels on the cell surface of CD34 þ cells (data not shown). Based on the CD95 expression levels measured on CD34 þ cells after IFN-g treatment, we expected hematopoietic progenitor cells to be susceptible to CD95-induced apoptosis. In order to induce apoptosis, we incubated CD34 þ cells (Figure 2a ) with 1 mg/ml anti-APO-1, a CD95 agonistic antibody, and assayed apoptosis by measuring Annexin-V binding. However, we found that stimulation with anti-APO-1 did not induce apoptosis in isolated CD34 þ cells, irrespective of the IFN-g concentration used. Even extending the stimulation time to 48 h did not lead to a significant increase in cell death (data not shown). The ability of our crosslinking CD95 mAb to induce apoptosis was controlled by stimulating CEM cells with 1 mg/ml of the anti-APO-1, resulting in 75% specific apoptosis after 24 h (Figure 2a) . Triggering of IFN-g-treated, CD95-expressing CD34 þ cells with FasL (0.1 mg/ml) instead of anti-APO-1 also did not induce apoptosis. The FasL concentration used was sufficient to induce 58% apoptosis in CEM cells after 24 h (Figure 2b ). Furthermore, no CD95-induced apoptosis could be detected by Annexin/PI staining in CD34 þ cells from fresh bone marrow (BM) treated with crosslinking CD95 mAb (anti-APO-1) at a concentration of 1 mg/ml for 24 h Caspase-8L protects CD34 þ cells from CD95-mediated apoptosis A Mohr et al (data not shown). In conclusion, we found that human CD34 þ cells are resistant to CD95-induced apoptosis.
Human CD34 þ undergo apoptosis via the mitochondrial pathway in response to etoposide treatment
In order to determine whether CD34 þ cells are generally incapable of undergoing programmed cell death or whether the resistance is limited to death receptor-mediated apoptosis, we investigated the sensitivity of CD34 þ cells to etoposide, a cytotoxic drug known to activate the mitochondrial cell death pathway. As shown in Figure 3a , 58% of cultured CD34 þ cells were Annexin-V positive after 48 h. Thus, human CD34 þ cells are able to undergo stress-induced apoptosis.
To further elucidate the apoptotic machinery downstream of mitochondria, activated by both drug treatment and death receptor triggering, we assayed the ability of CD34 þ cells to release cytochrome c and to activate caspase-3 in response to crosslinking CD95 mAb and drug treatment by flow cytometry. As suspected, no cytochrome c or caspase-3 activation was found in CD34 þ cells after CD95 triggering (data not shown). In contrast, etoposide treatment of isolated Figure 3b , left panel). Thus, CD34 þ cells are generally able to elicit apoptotic responses and the observed resistance to receptor-mediated apoptosis in CD34 þ cells is most likely due to molecular events directly linked to death receptor-associated signaling.
CD34 þ cells express high levels of the antiapoptotic caspase-8L
Resistance to CD95 death receptor-mediated apoptosis may be caused by a lack of expression of key elements of CD95 signaling (FADD, . Therefore, we assayed for the presence of molecules participating in the CD95 death-inducing signaling complex (DISC). We detected FADD in human CD34 þ cells, which normally binds to caspase-8, leading to the initiation of the caspase cascade (Figure 4a ). Additionally, we investigated caspase-8 by immunoblot analysis. In contrast to Jurkat cells, used as positive control, the caspase-8 proforms (a and b, 55.4 and 53.7 kDa, respectively) were absent in human CD34 þ cells. Instead, hematopoietic progenitor cells expressed an approximately 32 kDa protein, which was detected by the caspase-8 antibody (Figure 4b ). The molecular weight of this band is similar to a reported caspase-8 splice variant, caspase-8L, which has been implicated in antiapoptotic mechanisms. We confirmed caspase-8L expression in human CD34 þ cells by RT-PCR analysis. To this end, total RNA of CD34 þ cells was reverse transcribed and then amplified by PCR with primers that specifically detect the caspase-8L cDNA (Figure 4b ). The identity of the PCR product as caspase-8L was confirmed by sequence analysis (data not shown). In addition, we could not detect caspase-10 in CD34 þ cells (Figure 4a ). These finding implicates the absence of caspase-8a/b and the presence of the antiapoptotic caspase-8L form in CD95-resistance mechanisms of CD34 þ cells.
Alternatively, other antiapoptotic factors could be involved in the resistance to CD95 death receptormediated apoptosis. FLIP has been identified as a major antiapoptotic molecule inhibiting death receptor signaling (Scaffidi et al., 1999a) . While c-FLIP has been reported to be expressed at very high levels in HSC (Kim et al., 2002) , we could not detect FLIP in our CD34 þ samples by Western blot analysis using the FLIP-specific NF6 antibody (Scaffidi et al., 1997 (Scaffidi et al., , 1999a Kirchhoff et al., 2000) However, CD34 þ cells express a highly abundant protein at approximately the molecular weight of FLIP (Figure 4c ). This protein can be visualized by Ponceau-S staining and detected by the secondary antibody (goat-anti-mouse HRP) alone, due to the high abundance of the protein and consequent unspecific binding of the secondary antibody. To remove this abundant protein, we precleared our lysates with goatanti-mouse IgG beads. We compared the lysate of CD34 þ cells with lysates obtained after preclearing by Western blot analyses, using protein extracts from FLIP overexpressing cells as positive control. As shown in Figure 4c , the amount of the abundant protein decreases after repeated preclearing steps. Thus in our assays, CD34 þ hematopoietic progenitor exhibit no detectable (Figure 4c ), supporting our hypothesis that caspase-8L might predominantly contribute to the CD95 resistance in CD34 þ cells.
Caspase-8L is expressed at high levels in leukemic blasts of FAB M0 phenotype
Given the characteristic expression of caspase-8L in CD34 þ cells, we examined whether caspase-8L expression was also found in leukemic blasts of stem cell phenotype. We investigated leukemic blasts from stem cell leukemia characterized by high levels of CD34 and CD117 (c-kit), representing a clonal expansion of primitive hematopoietic progenitor cells corresponding to FAB M0. Similar to caspase-8L expression in normal CD34 þ cells, we detected only caspase-8L protein and no caspase-8a/b in these leukemic blasts (Figure 4d ). Caspase-8L expression was confirmed by RT-PCR (data not shown) and by subsequent sequencing of the PCR products (data not shown).
In line with normal CD34 þ hematopoietic progenitor cells, caspase-8L expression was found in stem cell leukemic blasts, pointing to a wider role of caspase-8L in apoptosis resistance and leukemogenesis.
Caspase-8L inhibits CD95-induced apoptosis in hematopoietic cells and is recruited to the DISC Caspase-8L has been shown to inhibit death receptormediated apoptosis when overexpressed (Himeji et al., 2002) . To clarify the caspase-8L-mediated resistance mechanism in hematopoietic cells, we cloned caspase-8L from CD34 þ cells, and generated a caspase-8L (ÀV5 tag)-expressing lentivirus and an EGFP control vector, which efficiently transduced CEM and SKW cells that are leukemic cell lines of T-cell origin. Both cell lines were initially transduced with the EGFP-expressing virus to determine transduction rates. Such transduced cells were termed CEM-EGFP and SKW-EGFP, respectively. As shown in Figure 5a , the transduction efficiency measured by FACS analysis 48 h after transduction was 80% in CEM cells and 85% in SKW cells. The respective caspase-8L expression levels in cells transduced with the caspase-8L lentiviral vector (CEM- Figure 5 Caspase-8L inhibits apoptosis in hematopoietic leukemic cells in the presence of endogenous caspase-8a/b at the death receptor level. (a) Hematopoietic leukemic cells, CEM and SKW cells were transduced with a lentivirus-expressing EGFP. The transduction efficiency was 80% in CEM and 85% in SKW cells, determined by FACS analysis. (b) Caspase-8L expression was assessed by immunoblot. Western blot analysis with anti-V5 and anti-caspase-8 antibodies were carried out with cell lysates from SKW and CEM cells expressing EGFP and caspase-8L, respectively. An immunoblot using an anti-CuZnSOD antibody served as loading control. (c) At 48 h after viral transduction, EGFP and caspase-8L-expressing CEM and SKW cells were treated with 1 mg/ ml crosslinking CD95 mAB for 4 h. Apoptosis was measured by Nicoletti, resulting in 50-60% specific cell death in the EGFPexpressing cells, depending on the cell line. In contrast, 2-7% of caspase-8L-expressing cells underwent specific apoptosis. (d) SKW cells were transiently transduced with a lentivirus expressing EGFP or caspase-8L. After 48 h, SKW cells were stimulated with 1 mg/ml crosslinking CD95 mAB for 3 min. Precipitates of the DISC complexes, which form upon stimulation, were separated by SDS-PAGE, and analysed by Western blot. Caspase-8 and caspase-8L recruitment to the DISC was visualized by using a caspase-8-specific antibody. The presence of the transgenic caspase-8L in the DISC was additionally confirmed with an anti-V5 antibody Caspase-8L protects CD34 þ cells from CD95-mediated apoptosis A Mohr et al 8L, SKW-8L) were determined 48 h after transduction by Western blot analysis (Figure 5b) .
Transduced CEM and SKW cells, expressing EGFP or caspase-8L were stimulated with 1 mg/ml crosslinking CD95 mAB for 4 h, 48 h after lentiviral transduction (Figure 5c ). Apoptosis was measured by Nicoletti, resulting in 50% specific cell death in the CEM-EGFP cells and 60% specific apoptosis in the SKW-EGFP cells. These apoptosis rates did not differ from nontransduced parental cells (data not shown). In contrast, only 5% of CEM-8L and 2% of the SKW-8L cells underwent specific apoptosis (Figure 5c ). Despite the relative low caspase-8L expression levels, compared to the endogenous caspase-8a/b levels (Figure 5b) , the caspase-8L-mediated resistance to CD95 triggering is substantial, thus underlining its strong dominant negative antiapoptotic function.
Having demonstrated that caspase-8L can protect hematopoietic cells from signal-mediated apoptosis, we wanted to test how caspase-8L exerts its inhibitory effect. Similar to caspase-8, caspase-8L contains the tandem DEDs that homotypically interact with the adaptor protein FADD. To this end, two scenarios can be envisaged; caspase-8L might be corecruited to the DISC, blocking subsequent signaling events such as caspase activation, or caspase-8L might sequester DISC constituents, for example, FADD in the cytosol, thereby inhibiting the formation of the DISC altogether. Therefore, we lentivirally transduced SKW cells, known to be type I cells, forming a readily detectable DISC in response to death receptor triggering . In SKW cells, the transduction efficiency was approximately 85% as measured by FACS analysis after 48 h (Figure 5a) . We compared the DISCs formed after stimulation with the crosslinking CD95 mAB in SKW-EGFP and SKW-8L cells. While none of the caspase-8 isoforms was bound to the nonstimulated receptors, we detected the proapoptotic caspase-8a/b in stimulated SKW-EGFP cells and both, caspase-8a/b and the antiapoptotic caspase-8L in the DISC of stimulated SKW-8L cells. The detection of a DISC containing caspase-8a/b rules out a sequestering role of caspase-8L since this would not allow the recruitment of the two proapoptotic isoforms to the receptor. Hence, our finding is in accordance with the first scenario outlined above, which postulates an inhibitory function of caspase-8L directly at the death receptor level.
The stem cell caspase-8L splice program is retained in myeloid and lymphoid leukemic blasts Since leukemias are usually caused by oncogenic transformations in early progenitor cells, it might be possible that genetic programs characteristic of hematopoietic stem-and progenitor cells are retained, rendering cells immortal and thereby contributing to the malignant process. After having shown that caspase-8L is expressed in CD34 þ leukemic blasts from stem cell leukemia (M0) and that caspase-8L can also exert its function in the presence of endogenous caspase-8 even at comparably low levels, we set out to investigate the possibility that caspase-8L might have a wider role in resistance to cytokine-mediated tumor surveillance mechanisms and leukemogenesis. Therefore, we determined the caspase-8 status in leukemic blasts of different AML or ALL phenotypes by immunoblot analysis (Figure 6 ). Indeed, we found expression of caspase-8L protein in part of the lymphoid and myeloid leukemias examined, pointing to a more general role of caspase-8L in apoptosis resistance. Blocking apoptosis at critical stages of hematopoiesis might give rise to dysfunctional (leukemia) cell eradication due to ineffective signal transduction of extracellular proapoptotic cues.
Discussion
Previous studies have suggested that CD34 þ cells express low levels of CD95 (Sato et al., 1997; Barcena et al., 1999; Josefsen et al., 1999; Kim et al., 2002) and acquire sensitivity towards CD95-induced apoptosis after IFN-g-induced upregulation of CD95 as detected by inhibition of colony formation (Maciejewski et al., 1995a) . Despite these data, the issue of sensitivity to CD95-triggered apoptotic signaling is still controversial, since resistance to CD95-induced cell death has also been described (Kim et al., 2002) . In our analyses of unmanipulated CD34 þ cells, we found these hematopoietic progenitor cells to be resistant to CD95-mediated apoptosis and to express an antiapoptotic splice variant of caspase-8, caspase-8L. We therefore suggest that caspase-8L might predominantly contribute to the CD95 resistance in CD34 þ cells and in HSC-derived leukemias.
Interestingly, in contrast to data obtained in colony assays upon prolonged culture and exposure of CD34 þ cells to CD95 agonists, we could not detect IFN-ginduced sensitization for CD95-induced apoptosis in short-term culture (Stahnke et al., 1998) . This discrepancy might be due to differentiation of these cells upon prolonged culture in vitro. After 5 days of culture in vitro, we found that the original cells had almost completely lost their CD34 positivity and had differentiated towards the myeloid lineage accompanied by proliferation (data not shown). Myeloid cells have been shown to be indeed sensitive to CD95-induced apoptosis Figure 6 Leukemic blasts of different phenotypes vary in their ratio of caspase-8L and caspase-8a/b. Caspase-8L and caspase-8 expression was assessed by immunoblot analysis. Western blot analysis with anti-caspase-8 antibody was carried out with cell lysates from leukemic blasts obtained from patients with different phenotypes. The patients were diagnosed as AML (6/14) and ALL (8/14)
Caspase-8L protects CD34 þ cells from CD95-mediated apoptosis A Mohr et al (Iwai et al., 1994; Liles et al., 1996; Perlman et al., 2001) . In contrast to long-term culture, our short-term induction provides the opportunity to investigate apoptotic signaling in not yet differentiated bona fide CD34 þ cells. To exclude CD95 resistance induced by G-CSF (Philpott et al., 1997) , we compared CD95 sensitivity of G-CSF-mobilized progenitors to CD34 þ cells from human BM. We did not detect any differences in the susceptibility of CD34 þ cells, obtained either from human BM or after growth factor-induced mobilization. We therefore conclude that hematopoietic CD34 þ progenitor cells are constitutively resistant to CD95-mediated apoptosis, independent of the growth factors used for mobilization or of the microenvironment mediated by the cocultured cells, as demonstrated by the comparison of unselected leukapheresis material and total bone marrow (data not shown). CD95-mediated apoptotic signaling is initiated by formation of a DISC, a complex formed by multimerized CD95 attracting the adaptor protein FADD and caspase-8 as initiator caspase. Two different CD95 apoptosis signaling cell types have been identified . In type I cells, activation of caspase-8 occurs at the DISC, followed by activation of the caspase cascade. In type II cells DISC formation is limited, but still required, and cytochrome c release from the mitochondria seems to be essential to amplify the apoptotic signal and to activate downstream effector caspases (e.g. caspase-3) . Independent of the respective signaling cell types, the apoptotic pathways converge on the level of effector caspases. Etoposide treatment revealed that CD34 þ cells are generally able to undergo apoptosis elicited by a stressinducing stimulus and resistance to receptor-mediated apoptosis in CD34 þ cells most likely resides at the level of death receptor triggering.
Molecular analyses have attributed CD95 resistance in CD34 þ cells to expression of FLIP, an endogenous inhibitor of CD95 signaling, which prevents caspases from binding to FADD containing multimerized CD95 receptors (Kim et al., 2002) . We detected FADD but we could not detect FLIP protein in CD34 þ cells. Other known inhibitors of apoptosis shown to be present in CD34 þ cells such as survivin or IAPs (inhibitor of apoptosis proteins) act downstream of the death receptor and in view of the chemosensitivity of CD34 þ cells appear to have no fundamental role in the regulation of apoptosis in these cells. Interestingly, we could not detect the functional proforms of caspase-8. Instead of caspase-8a/b, caspase-8L was found in CD34 þ cells. Caspase-8L was shown to be generated by aberrant splicing of intron 8, carrying a 136-bp insertion and frame shift of the transcript. The transcript encodes the DEDs of caspase-8, but lacks the C-terminal half of the proteolytic domain (Horiuchi et al., 2000) . Caspase-8L was found to act as an inhibitor of CD95-mediated death signaling by competing with the caspase-8/FADD interaction by binding to FADD or to caspase-8 in MCF-7 cells overexpressing caspase-8L (Himeji et al., 2002) . However, the exact function of caspase-8L with regard to DISC formation and its potential role within this complex remained unaddressed in the above-cited study.
To clarify this point, we lentivirally transduced CEM and SKW cells with caspase-8L and subjected them to death receptor triggering. We found that caspase-8L can indeed act as an inhibitor of CD95-mediated apoptosis signaling in these leukemic cell lines. Analyses of type I (SKW) cells revealed that caspase-8L exerts its antiapoptotic function at the death receptor level, since it is recruited to the DISC in response to CD95 triggering. At the receptor level, caspase-8L can block death receptor-mediated apoptosis in the presence of endogenous initiator caspases (caspase-8 and caspase-10), even at comparably low levels, and it was able to inhibit apoptosis even in SKW cells known to express relatively high levels of caspase-8a/b Scaffidi et al., 1999b) . Our data point to a dominant negative role of caspase-8L allowing full DISC formation including FADD, caspase-8a/b, and caspase-8L itself, however blocking final activation of caspase-8. This becomes evident by lack of activity of the caspase-8 target caspase-3 in CEM-8L cells (data not shown). Therefore, we hypothesize that in the presence of caspase-8L and its stimulation induced aberrant cleavage product, the formation of the normal p10/p18 active caspase-8 heterodimer is inhibited, leading to signal-mediated apoptosis resistance.
CD34 þ hematopoietic progenitors are protected from neighboring cells, expressing CD95L and might therefore guarantee the generation or maintenance of HSC. Further maturation steps include the acquisition of CD95 sensitivity to control homeostasis. Failure to develop CD95 sensitivity during maturation of HSC may constitute a malignant hit, since blockage of CD95-induced apoptosis may promote resistance to immunebased destruction and may create a permissive environment for genetic instability and accumulations of gene mutations, resulting in the development of leukemia (Straus et al., 2001; Sugahara et al., 2002) . In line with our hypothesis, that caspase-8L expression might contribute to the protection of hematopoietic progenitor cells from death receptor-triggered apoptosis, we found caspase-8L expression in the absence of caspase-8a/b in four out of four patients suffering from stem cell leukemia (FAB M0). Thus, stem cell-derived blasts appear to have lost the capability to respond to differentiation-inducing stimuli and to switch from caspase-8L to caspase-8 expression or they are frozen at an insensitive caspase-8L-expressing stage, thereby maintaining the CD95 resistant state of HSCs. Furthermore, we found caspase-8L expression in various samples from AML and ALL patients. These findings extent the potential role of caspase-8L from leukemias corresponding to FAB M0 to forms of disease representing more mature, lineage committed hematopoietic cells.
Taken together, alternative splicing of caspase-8 represents a potential control mechanism during hematopoiesis, modulating sensitivity to death receptormediated apoptosis. With ongoing activation or differentiation cells become sensitive to death receptor Caspase-8L protects CD34 þ cells from CD95-mediated apoptosis A Mohr et al triggering and can be eliminated to turn off hematopoiesis and immune responses. Failure to reprogram this tightly controlled apoptosis susceptibility mechanism at the transition from HSC to progenitor cells and on to mature effector cells might contribute to the development of leukemia.
Materials and methods

Cell cultures
Aliquots of human cryopreserved CD34 þ cells were thawed as previously described (Kim et al., 2002) . CD34 þ cells were plated at 5 Â 10 5 -1 Â 10 6 cells/ml in 24-well tissue culture plates (Greiner, Nu¨rtingen, Germany) in stem cell medium containing IL-3 (100 ng/ml), SCF (100 ng/ml), and FLT-3 (300 ng/ml) (R&D, Minneapolis, MN, USA) and incubated in a 5% CO 2 -humidified atmosphere at 371C. We received informed consent from all donors whose samples were used in this study. The study protocol was approved by the local ethics committee.
Antibodies (Ab)
Flow cytometry: Anti-CD95 APC-conjugated antibody and isotype matched control, purchased from BD Bioscience (BD Bioscience, San Jose, CA, USA). Immunoblot: Anti-caspase-8 (BD Pharmingen, San Diego, CA, USA and Santa Cruz, Santa Cruz, CA, USA), anti-caspase-10 (MBL international, Woburn, MA, USA), sheep anti-human-CuZnSOD antibody (The Binding Site, Birmingham, UK), anti-FADD mAB (Upstate Biotechnology Lake Placid, NY, USA), anti-V5 mAb (Invitrogen, Carlsbad, CA, USA), the anti-c-FLIP mAB NF6 (mouse IgG1) was provided by Peter Krammer (Scaffidi et al., 1997 (Scaffidi et al., , 1999a , horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG and mouse anti-rabbit IgG antibodies (Santa Cruz, Santa Cruz, CA, USA), HRP-conjugated donkey antisheep IgG antibody (Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA).
RNA extraction and RT reaction
Total RNA was isolated using the RNAeasy Kit (Qiagen, Hilden, Germany) following the manufacturer's instructions. The RT reaction was conducted using the First-Strand cDNA Synthesis Kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions.
PCR analysis
To determine the expression of the different isoforms of caspase-8 messenger RNA (mRNA) in different cell types, the synthesized cDNAs were amplified by PCR: after 5 min incubation at 941C, PCR was carried out for 60 s at 941C, 120 s at 501C, and 180 s at 721C for 30 cycles. Caspase-8L PCR was conducted using two primers, 5 0 -caa atg caa act gga tga tga c (5 0 -primer) and 5 0 -gcc ctt ttg gta tag ctt ttg ttc (3 0 -primer).
For sequence analysis, the PCR-fragment was purified and cloned into a pGEM-T-easy vector (Promega, Madison, WI, USA).
Western blot analysis
Cell lysis and immunoblotting was performed according to a previously described protocol (Zwacka et al., 2000) .
Cell death and apoptosis measurements
Apoptosis was measured by two different methods: Annexin-V/PI staining and Nicoletti staining (Nicoletti et al.,) . For the induction of apoptosis, cells were pretreated with IFN-g at the indicated concentrations (R&D, Minneapolis, MN, USA) followed by 1 mg/ml anti-APO-1 or 0.1 mg/ml FasL treatment. To control the ability to undergo apoptosis, cells were treated with etoposide (Sigma-Aldrich, St Louis, MS, USA). In both methods, specific apoptosis was calculated by subtracting values of basal apoptosis (medium) from values of induced apoptosis.
Analysis of cytochrome c release
Analysis of cytochrome c release and caspase-3 activation was performed to a recently described protocol (Stahnke et al., 2004) .
Caspase-8L lentivirus
293FT cells were cotransfected with pGJ3-EGFP or pGJ3-caspase-8L (Jarmy et al., 2001 ) and the env expression plasmid pczVSV-G containing the vesicular stomatitis virus G glycoprotein (VSV-G) gene (Pietschmann et al., 1999) by using Fugene (Roche, Penzberg, Germany). Cell culture supernatants containing the viral vectors were harvested after 72 h, filtered, concentrated (100-fold) by centrifugation in 100 000 MW cutoff Centricon filters and used to infect CEM and SKW cells. Cells (1 Â 10 5 ) were resuspended in 3 ml of the virus-containing supernatant and centrifuged for 2 h at 321C. After an additional 3 h incubation at 371C, cells were resuspended in fresh prewarmed RPMI medium and analysed for transgene expression after 48 h.
DISC assay
Analysis of the CD95-DISC was performed according to a recently described protocol (Strauss et al., 2003) .
